| Literature DB >> 35023848 |
Thiago Silva Torres1, Emilia Moreira Jalil1, Lara Esteves Coelho1, Daniel Rodrigues Barros Bezerra1, Cristina Moreira Jalil1, Brenda Hoagland1, Sandra Wagner Cardoso1, Sean Arayasirikul2,3, Valdilea Gonçalves Veloso1, Erin C Wilson2, Willi McFarland2, Beatriz Grinsztejn1.
Abstract
BACKGROUND: In many parts of the world, including Brazil, uptake for biomedical interventions has been insufficient to reverse the HIV epidemic among key populations at high risk for HIV, including men who have sex with men. Young MSM (YMSM), particularly Black YMSM, have high HIV incidence, low viral suppression, and low preexposure prophylaxis (PrEP) uptake and adherence. Therefore, novel approaches to increase the HIV biomedical interventions uptake by YMSM are urgently needed.Entities:
Keywords: Brazil; HIV; HIV prevention; sexual and gender minorities; technology-based adherence intervention; young MSM
Year: 2022 PMID: 35023848 PMCID: PMC8796043 DOI: 10.2196/34885
Source DB: PubMed Journal: JMIR Res Protoc ISSN: 1929-0748
Figure 1Digital coupon for the Conectad@s Project recruitment. Legend: Coupon used by seeds to recruit peers to the project, with the name (Conectad@s) followed by “we are strong,” inclusion criteria (18-24 years) and invitation to participate in the project only if coupon was received from a friend or acquaintance. Phone number and WhatsApp contact information to schedule an appointment are provided with a statement that scheduling is required.
Behavioral, partnership, network, and structural measures for the RDSa-based study.
| Timeframe | Level/domain | Examples of measures/hypotheses |
| Acute infection: within the last several weeks | Individual | Events of likely acquisition and transmission; missed opportunities for prevention; STIb co-infection. |
| Partnership | Characteristics of most recent sexual partners (HIV status, disclosure, on ARTc, PrEPd, and age) [ | |
| Recent infection: within last 130-180 days | Individual | Missed opportunities for prevention; untreated STIs; HIV care cascade. |
| Sexual network, with a focus on Black/ | Characteristics of recent sexual partners; age and racial mixing, with a specific focus on sexual networks of Black/ | |
| Long-standing infection: since the onset of risk or last HIV test | Previously undiagnosed | Missed opportunities for testing, linkage to care, experiences, and attitudes towards care providers. |
| Previously diagnosed | Barriers to care, ART initiation, adherence [ | |
| All (including and regardless of HIV status): since the onset of risk | Demographic | Racial disparities in risk, prevention, and care access (eg, race/ethnicity and socioeconomic status); homelessness, runaway; incarceration; digital health information. |
| Risk and prevention | Onset of sexual risk, lifetime risk; substance use and chemsex [ | |
| Psychosocial, structural | Mental health [ | |
| Health and social welfare systems | Care-seeking and medical mistrust; health care participation; avoidance of care; perceived care access; “ |
aRDS: respondent-driven sampling.
bSTI: sexually transmitted infection.
cART: antiretroviral therapy.
dPrEP: preexposure prophylaxis.
eSUS: Sistema Único de Saúde (Brazilian National Public Health System).
Schedule of events for the Conectad@s Project.
|
| RDSa/ | Week 4 | Week 12 | Week 24 | Week 36 | Week 48 | Early Terminationb | HIV seroconversion visit | Unscheduled visit | ||||||||||
|
| |||||||||||||||||||
|
| Behavioral, partnership, network, and structural measures | X | X | X | X | X | X | X | —c | — | |||||||||
|
| Technology-based intervention: inclusion | X | — | — | — | — | — | — | — | — | |||||||||
|
| Technology-based intervention: acceptability | — | — | — | X | — | — | — | — | — | |||||||||
|
| |||||||||||||||||||
|
| HIV antigen rapid test | X | Xd | Xd | Xd | Xd | Xd | Xd | X | Xe | |||||||||
|
| HIV RNAPool | Xf | Xf | Xf | Xf | Xf | Xf | Xf |
| Xf | |||||||||
|
| HIV RNA viral load | Xg | Xh | Xh | Xg | Xh | Xg | Xg | X | Xe | |||||||||
|
| CD4/CD8 | Xi | Xj | Xj | Xi | Xj | Xi | Xi | X | Xe | |||||||||
|
| HIV recency testing | Xi | — | — | — | — | — | — | — | Xe | |||||||||
|
| HIV genotyping | Xk | Xl | — | — | — | — | — | X | Xe | |||||||||
|
| Urine (CTm/NGn) | X | — | — | X | — | X | X | X | — | |||||||||
|
| Oropharyngeal swab (CT/NG) | X | — | — | X | — | X | X | X | — | |||||||||
|
| Anal swab (CT/NG) | X | — | — | X | — | X | X | X | — | |||||||||
|
| Anal swab (HPVo) | X | — | — | — | — | — | — | — | — | |||||||||
|
| Anal cytology | X | — | — | — | — | — | — | — | — | |||||||||
|
| Hepatitis B rapid test | X | — | — | — | — | Xp | Xp | Xp | Xe | |||||||||
|
| Hepatitis B serology | Xq | — | — | — | — | Xq | Xq | Xq | Xe | |||||||||
|
| Hepatitis C rapid test | X | — | — | — | — | Xr | Xr | Xr | Xe | |||||||||
|
| Anti-HCV | Xs | — | — | — | — | Xs | Xs | Xs | Xe | |||||||||
|
| RNA Hepatitis C viral load | Xt | — | — | — | — | Xt | Xt | Xt | Xe | |||||||||
|
| Treponemal syphilis rapid test | X | — | X | X | X | X | X | X | Xe | |||||||||
|
| Non-treponemal syphilis testing (VDRL) | Xu | — | Xu | Xu | Xu | Xu | Xu | Xu | Xe | |||||||||
|
| DBSv (PrEP adherence assessment) | Xw | Xw | Xw | Xw | Xw | Xw | Xw | Xw | Xe | |||||||||
|
| Creatinine | Xx | Xf | Xf | Xx | Xf | Xx | Xx | Xf | Xe | |||||||||
|
| Complete blood count | Xf | Xf | Xf | Xf | Xf | Xf | Xf | Xf | Xf | |||||||||
aRDS: respondent-driven sampling.
bWithdrawn or discontinued participants before the final visit.
cNot applicable
dOnly for HIV-negative participants in a prior visit.
eIf necessary.
fOnly for postexposure prophylaxis use.
gOnly for HIV-positive participants or HIV-negative participants with recent HIV exposition according to INI-Fiocruz guidelines (HIV acute infection screening).
hOnly for HIV-negative participants with recent HIV exposition according to INI-Fiocruz guidelines (HIV acute infection screening).
iOnly to HIV-positive participants or to participants with HIV rapid test, HIV RNA Pool or HIV RNA viral load positive result.
jOnly to participants with HIV rapid test, HIV RNA Pool or HIV RNA viral load positive result, with negative HIV rapid test in a prior visit.
kOnly HIV-positive participants ART naïve
lOnly HIV-positive participants with prior ART use (before study initiation).
mCT: Chlamydia trachomatis.
nNG: Neisseria gonorrhea.
oHPV: human papilloma virus.
pOnly for negative Hepatitis B rapid test at baseline.
qOnly for positive Hepatitis B rapid test.
rOnly for negative Hepatitis C rapid test at baseline.
sOnly for positive Hepatitis C rapid test.
tOnly for positive anti-HCV.
uOnly treponemal syphilis rapid test.
vDBS: Dried blood spot.
wOnly for participants using PrEP.
xOnly for participants using PrEP or PEP.
Planned activities for the Conectad@s Project.
| Activities | 2022 | 2023 | |||||||
|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| Formative phase analysis | x | —a | — | — | — | — | — | — | |
| Dissemination of formative results | — | x | — | — | — | — | — | — | |
| Manual of operations approval | x | — | — | — | — | — | — | — | |
| Training | x | — | — | — | — | — | — | — | |
| Investigators’ meetings | x | — | — | — | x | — | — | — | |
| RDSb survey and intervention enrollment | x | x | x | — | — | — | — | — | |
| Follow-up for intervention | — | x | x | x | x | x | — | — | |
| RDS survey analysis | — | — | x | — | — | — | — | — | |
| Dissemination of RDS results | — | — | — | x | — | — | — | — | |
| Intervention analysis | — | — | — | — | — | — | x | — | |
| Dissemination of intervention results | — | — | — | — | — | — | — | x | |
aNot applicable.
bRDS: respondent-driven sampling.